Skip to main content

Ipratropium nasal Disease Interactions

There is 1 disease interaction with ipratropium nasal.

Moderate

Inhaled anticholinergic agents (applies to ipratropium nasal) anticholinergic effects

Moderate Potential Hazard, Low plausibility. Applicable conditions: Urinary Retention, Glaucoma (Narrow Angle)

Aclidinium, ipratropium, umeclidinium, and tiotropium are anticholinergic agents. Although systemic effects are uncommon due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa, worsening of urinary retention or angle-closure glaucoma has been reported. Increased intraocular pressure and precipitation or exacerbation of angle-closure glaucoma may also occur due to inadvertent contact of the eye with aerosolized or nebulized drug. Accordingly, therapy with quaternary ammonium compounds should be administered cautiously in patients with urinary retention/obstruction or angle-closure glaucoma. Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation or use of a mouthpiece rather than face mask during nebulization. Patients should be advised to contact their physician if they experience urinary difficulty (especially in patients with prostatic hyperplasia or bladder neck obstruction); or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).

References

  1. Gross NJ (1988) "Ipratropium bromide." N Engl J Med, 319, p. 486-94
  2. Milford CA, Mugliston TA, Lund VJ, Mackay IS (1990) "Long-term safety and efficacy study of intranasal ipratropium bromide." J Laryngol Otol, 104, p. 123-5
  3. Lozewicz S (1989) "Bladder outflow obstruction induced by ipratropium bromide." Postgrad Med J, 65, p. 260-1
  4. Pras E, Stienlauf S, Pinkhas J, Sidi Y (1991) "Urinary retention associated with ipratropium bromide." DICP, 25, p. 939-40
  5. Massey KL, Gotz VP (1985) "Ipratropium bromide." Drug Intell Clin Pharm, 19, p. 5-12
  6. Pakes GE, Brogden RN, Heel RC, Speight TM, Avery GS (1980) "Ipratropium bromide: a review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis." Drugs, 20, p. 237-66
  7. (2002) "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim
  8. "Product Information. Atrovent Nasal (ipratropium nasal)." Boehringer-Ingelheim
  9. (2002) "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim
  10. (2012) "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals
  11. (2014) "Product Information. Incruse Ellipta (umeclidinium)." GlaxoSmithKline
View all 11 references

Ipratropium nasal drug interactions

There are 84 drug interactions with ipratropium nasal.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer